What companies make COVID vaccines?

Companies making COVID vaccines include: Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), and Novavax (NASDAQ:NVAX).

What is the future price of MRNA stock?

There's no way to predict the future price of Moderna (NASDAQ:MRNA) stock. However, the company has several promising candidates in its pipeline that could drive its share price higher over the next few years.

Pfizer (NYSE:PFE) is a publicly traded company owned by its shareholders. The drugmaker's largest shareholders include Vanguard Group, BlackRock (NYSE:BLK), and State Street (NYSE:STT).

Are vaccine stocks safe investments?

Vaccine stocks shouldn't be viewed as highly safe investments. These stocks can have significant risks, including clinical setbacks and regulatory failures. However, investors can mitigate the risks associated with investing in vaccine stocks by diversifying, focusing primarily on established players with long track records of success, and maintaining a long-term mindset.

What is the most successful vaccine ever?

The smallpox vaccine is probably the most successful vaccine in history. Developed by Edward Jenner at the end of the 18th century, this vaccine eventually eradicated the smallpox virus that had killed hundreds of millions of people in the past.

Best Vaccine Stocks of 2026: Are They Right for Your Portfolio?

Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.

By Keith Speights – Updated Feb 5, 2026 at 5:42 PM EST | Fact-checked by Frank Bass

Key Points

Vaccine stocks remain lucrative, with ongoing revenue from both COVID-19 and other vaccines.
Before investing, assess a company's market products, regulatory status, and potential issues.
Research pipeline drugs and other pharmaceutical products to minimize risk and enhance returns.

COVID-19 isn't as concerning to many Americans as it was in 2020. Unsurprisingly, sales of COVID-19 vaccines have plunged. Does that mean investors should throw in the towel on vaccine stocks? Not at all. Vaccine stocks are shares of publicly traded companies involved in the development of vaccines that immunize against many disease-causing microorganisms -- not just the virus that causes COVID-19.

For one thing, COVID-19 vaccines continue to generate significant revenue despite the sales declines. More importantly, there are lots of other types of vaccines that are key growth drivers for some pharmaceutical companies.

Here's what you need to know about investing in the top vaccine stocks, along with our top vaccine stock picks.

Loading paragraph...

Ticker Information Table
Name and ticker	Market cap	Dividend yield	Industry
Pfizer (NYSE:PFE)	$157.2 billion	6.22%	Pharmaceuticals
BioNTech Se (NASDAQ:BNTX)	$26.5 billion	0.00%	Biotechnology
Moderna (NASDAQ:MRNA)	$21.2 billion	0.00%	Biotechnology
GSK (NYSE:GSK)	$119.3 billion	3.02%	Pharmaceuticals
Bavarian Nordic A/s (OTC:BVNRY)	$2.4 billion	0.00%	Biotechnology
Emergent BioSolutions (NYSE:EBS)	$428.0 million	0.00%	Biotechnology

Data as of Mar 1, 2026. Showing 6 of 6 tickers.

Loading ticker_table...

Loading paragraph...

NYSE: PFE

Pfizer

Today's Change

(1.94%) $0.53

Current Price

$27.63

Key Data Points

Market Cap

$157B

Day's Range

$27.09 - $27.66

52wk Range

$20.91 - $27.94

Volume

1.2M

Avg Vol

48M

Gross Margin

66.23%

Dividend Yield

6.22%

Loading company_card...

Pfizer (PFE +1.94%) made a great decision in 2020 when it teamed up with German biotechnology company BioNTech (BNTX +1.30%) to develop a COVID-19 vaccine. The vaccine, given the brand name Comirnaty, was the first to win U.S. approval and was a massive commercial success for Pfizer -- at least for a few years.

Dwindling sales for Comirnaty have caused Pfizer's revenue to sink and have taken a steep toll on the pharmaceutical company's stock. However, Pfizer has two other vaccines on the market that generate significant revenue: pneumococcal vaccine Prevnar 20 and respiratory syncytial virus (RSV) vaccine Abrysvo.

Pfizer's pipeline features several other vaccines that are in development. They include Lyme disease vaccine PF-07307405, streptococcus vaccine PF-06760805, and influenza vaccine PF-07252220.

Vaccines aren't the only products that could contribute to Pfizer's growth, though. The company also markets drugs that treat a wide variety of conditions, including autoimmune diseases, cancer, and migraine. In addition, Pfizer pays an attractive dividend, making the stock a favorite of income-seeking investors.

2. BioNTech

Loading paragraph...

NASDAQ: BNTX

BioNTech Se

Today's Change

(1.30%) $1.42

Current Price

$110.22

Key Data Points

Market Cap

$27B

Day's Range

$109.40 - $110.97

52wk Range

$81.20 - $124.00

Volume

16K

Avg Vol

1.1M

Gross Margin

82.79%

Loading company_card...

Loading paragraph...

NASDAQ: MRNA

Moderna

Today's Change

(3.60%) $1.86

Current Price

$53.57

Key Data Points

Market Cap

$21B

Day's Range

$50.73 - $53.62

52wk Range

$22.28 - $55.20

Volume

9.1M

Avg Vol

12M

Gross Margin

44.29%

Loading company_card...

Moderna (MRNA +3.60%) quickly followed Pfizer and BioNTech in winning U.S. approval for its COVID-19 vaccine. Although sales for this vaccine, marketed under the brand name SpikeVax, have deteriorated, it remains a major source of revenue for the company.

SpikeVax is no longer Moderna's only approved product, though. The company won U.S. approval in May 2024 for its RSV vaccine mResvia and for its next-generation COVID-19 vaccine mNEXSPIKE in 2025.

Moderna could have additional new products on the way. The list includes a seasonal flu vaccine and a combination COVID-19/flu vaccine. The company is working with Merck (MRK +3.79%) in the late-stage development of cancer vaccine mRNA-4157. Its pipeline also includes experimental vaccines and therapies in phase 1 and phase 2 testing that are targeting several viruses and rare diseases.

Loading paragraph...

4. GSK

Loading paragraph...

NYSE: GSK

GSK

Today's Change

(1.70%) $0.99

Current Price

$59.06

Key Data Points

Market Cap

$119B

Day's Range

$58.34 - $59.36

52wk Range

$32.38 - $61.70

Volume

242K

Avg Vol

Gross Margin

72.53%

Dividend Yield

3.02%

Loading company_card...

GSK (GSK +1.82%) wasn't a major player in the COVID-19 vaccine market. However, the big pharmaceutical company has 17 other approved vaccines, including Shingrix, which is a shingles vaccine.

Like Pfizer and Moderna, GSK markets an RSV vaccine for adults. The company won U.S. approval for the vaccine, which has the brand name Arexvy, in May 2023 for immunizing older adults and in June 2024 for adults ages 50 through 59.

GSK won U.S regulatory approval in February 2025 for meningitis vaccine Penmenvy. It is also evaluating several vaccines in late-stage clinical trials.

Vaccines aren't GSK's only focus, though. The drugmaker also markets medications targeting cancer as well as cardiovascular, neurological, and respiratory diseases.

Loading paragraph...

OTC: BVNRY

Bavarian Nordic A/s

Today's Change

(0.46%) $0.05

Current Price

$10.34

Key Data Points

Market Cap

$2.4B

Day's Range

$10.34 - $10.44

52wk Range

$6.59 - $13.00

Volume

523

Avg Vol

1.8K

Gross Margin

54.01%

Loading company_card...

Emergent Biosolutions (EBS -26.35%) is probably best known for its anthrax vaccines and Narcan nasal spray for the emergency treatment of opioid overdoses. However, the company also markets other products, including smallpox and mpox vaccine ACAM2000.

Loading paragraph...

NYSE: EBS

Emergent BioSolutions

Today's Change

(-26.35%) $-2.92

Current Price

$8.18

Key Data Points

Market Cap

$428M

Day's Range

$8.01 - $9.52

52wk Range

$4.02 - $14.06

Volume

166K

Avg Vol

878K

Gross Margin

47.07%

Loading company_card...

Loading paragraph...

Vaccine stocks FAQ

Loading faq...

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

TMFFishBiz

Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Merck, Moderna, and Pfizer. The Motley Fool recommends BioNTech Se, Emergent BioSolutions, and GSK. The Motley Fool has a disclosure policy.

Best Vaccine Stocks to Buy in 2026: Are They Right for Your Portfolio?

Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.

Key Points

Key Data Points

2. BioNTech

Key Data Points

Key Data Points

4. GSK

Key Data Points

Key Data Points

Key Data Points

Related investing topics

Best Healthcare Stocks to Buy in 2026 and How to Invest in Them

Biotech vs. Pharma: What's the Difference?

Pharmaceutical tariffs: Which countries does the U.S. import the most from?

Best Biotech Stocks to Buy in 2026 and How to Invest in Them

Vaccine stocks FAQ

What companies make COVID vaccines?

What companies make COVID vaccines?

What is the future price of MRNA stock?

What is the future price of MRNA stock?

Who owns Pfizer?

Who owns Pfizer?

Are vaccine stocks safe investments?

Are vaccine stocks safe investments?

What is the most successful vaccine ever?

What is the most successful vaccine ever?

About the Author

Stocks Mentioned

Premium Investing Services

Vaccine stocks FAQ

What companies make COVID vaccines?

What companies make COVID vaccines?

What is the future price of MRNA stock?

What is the future price of MRNA stock?

Who owns Pfizer?

Who owns Pfizer?

Are vaccine stocks safe investments?

Are vaccine stocks safe investments?

What is the most successful vaccine ever?

What is the most successful vaccine ever?

Best Healthcare Stocks to Buy in 2026 and How to Invest in Them

Biotech vs. Pharma: What's the Difference?

Pharmaceutical tariffs: Which countries does the U.S. import the most from?

Best Biotech Stocks to Buy in 2026 and How to Invest in Them

Key Data Points

Top vaccine stocks to consider

1. Pfizer

4. GSK

What to know about investing in vaccine stocks

Global vaccine market outlook

Related investing topics

FAQ

Key Data Points

Key Data Points

Key Data Points

Key Data Points

Key Data Points

2. BioNTech

3. Moderna

Other vaccine stocks to watch